FluMist Quadrivalent: alternative to Fluenz Tetra

FluMist Quadrivalent is an intranasal influenza vaccine that can be used to vaccinate children once supplies of Fluenz Tetra are exhausted.

Despite the wording on the packaging, in the UK FluMist Quadrivalent should only be used in children between 24 months and 18 years of age.

As a result of a supply shortage there are insufficient supplies of Fluenz Tetra to meet the timelines for the 2015/16 influenza vaccination programme. In order to cover the deficit, AstraZeneca has reached an agreement with the MHRA to supply two batches of pharmaceutically identical US labelled FluMist Quadrivalent in addition to the usual Fluenz Tetra stock. Supplies of FluMist Quadrivalent will be distributed once existing stocks of Fluenz Tetra have been delivered.

Further information
View Fluenz Tetra drug record
Summary of Product Characteristics
Manufacturer: AstraZeneca

As the two products are identical all FluMist Quadrivalent packs will be supplied with a UK PIL which should be made available with each dose. The US leaflet in the packs should be discarded. FluMist Quadrivalent should be used in accordance with the UK SPC for Fluenz Tetra.

The FluMist Quadrivalent batches being supplied (FL2113 & FL2118) must not be used after February 24th 2016. A pre-planned withdrawal of any unused stock will begin on January 25th 2016.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...